Technology development in high-potency, biologics and sterile pharmaceutical products
First written in FY2016. 5 of 7 entries say "Advanced", first in FY2019. Latest entry: FY2025.
1 other company's latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「In the development of continuous manufacturing technology for active pharmaceutical ingredients for small-molecule pharmaceuticals, we began commercializing the iFactory developed under NEDO’s Strategic Energy-Saving Technology Innovation Program. For middle-molecule and biopharmaceuticals, we obtained 4 patents by fiscal 2024 through the development of automated equipment using single-use technology, and delivered equipment for continuous purification processes and labor-saving systems for processes including inactivation, clarification, sterile filtration and filling.」
We began commercializing iFactory, while the number of patents obtained for middle-molecule and biopharmaceutical applications increased to 4 by fiscal 2024. Delivery of labor-saving systems is continuing. - FY2024AdvancedAnnual report
「In the development of continuous manufacturing technology for active pharmaceutical ingredients for small-molecule pharmaceuticals, the “iFactory for Pharmaceutical Manufacturing Based on Interconnection of Reconfigurable Modular Unit Operations,” developed under NEDO’s Strategic Energy-Saving Technology Innovation Program, was recognized for its achievements and received the following awards: Fiscal 2022 “Japan Open Innovation Prize, Minister of Economy, Trade and Industry Award” Fiscal 2023 “NEDO Energy-Saving Technology Development Award,” Chairman’s Award Fiscal 2023 “Engineering Achievement Award, Special Encouragement Award”」
For iFactory, 3 awards received in fiscal 2022 and fiscal 2023 are reported. For middle-molecule and biopharmaceuticals, the company also reports the acquisition of 3 patents by fiscal 2023 and delivery of labor-saving systems. - FY2023AdvancedAnnual report
「In the development of continuous manufacturing technology for active pharmaceutical ingredients for small-molecule pharmaceuticals, the first unit of “iFactory for Pharmaceutical Manufacturing Based on Interconnection of Reconfigurable Modular Unit Operations,” developed under NEDO’s Strategic Energy-Saving Technology Innovation Program, was completed in February 2023. For middle-molecule and biopharmaceuticals, we obtained 3 patents by fiscal 2022 through the development of automated equipment using single-use technology, and delivered equipment for continuous purification processes and labor-saving systems for processes including inactivation, clarification and sterile filtration.」
In the pharmaceutical field, specific progress included completion of the first iFactory unit in February 2023, acquisition of 3 patents by fiscal 2022, and delivery of multiple labor-saving systems. - FY2021AdvancedAnnual report
「Along with advances in continuous manufacturing technology for active pharmaceutical ingredients for small-molecule pharmaceuticals, we developed modular equipment and mobile dust collection equipment for highly potent active pharmaceutical ingredients, leading to delivery of commercial units in fiscal 2020. For middle-molecule and biopharmaceuticals, we developed automated equipment using single-use technology and delivered operating equipment for continuous purification processes in fiscal 2020.」
In the pharmaceutical field, progress was made through delivery in fiscal 2020 of modular equipment and mobile dust collection equipment for small-molecule pharmaceuticals, and continuous purification process equipment for middle-molecule and biopharmaceuticals. - FY2019AdvancedAnnual report
「We have also begun developing manufacturing technologies for middle-molecule pharmaceuticals, for which future growth is expected.」
In addition to conventional small-molecule pharmaceuticals, highly potent active pharmaceutical ingredients and biopharmaceuticals, we have begun developing manufacturing technologies for middle-molecule pharmaceuticals. - FY2017RestatedAnnual report
「In the pharmaceutical field, we continue research and development of related technologies to address a wide range of needs, including the production of highly potent pharmaceuticals, biopharmaceuticals and sterile pharmaceuticals.」
We continue research and development aimed at meeting the needs of highly potent, biopharmaceutical and sterile pharmaceuticals. The text also identifies dust collection equipment, single-use automated equipment and continuous manufacturing equipment as development targets. - FY2016First statedAnnual report
「In the pharmaceutical field, we continue research and development of related technologies to address a wide range of needs, including the production of highly potent pharmaceuticals, biopharmaceuticals and sterile pharmaceuticals.」
Development targets include simulated powder measurement, 3D printers, single-use automated equipment and aseptic processing technologies.